Changes

60. Watanabe T, et al., (2009). Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol (Berl) 117:653–656, PMID 19340432.  

60. Watanabe T, et al., (2009). Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol (Berl) 117:653–656, PMID 19340432.  

61. The Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 372, 2481–2498 (2015). PMID: 26061751  

61. The Cancer Genome Atlas Research Network. Comprehensive, (2015).Integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498, PMID 26061751.

62. Chou, W.-C. et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25, 246–253 (2011). PMID: 21079611  

62. Chou W-C, et al., (2011). The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25:246–253, PMID 21079611.

63. Marcucci, G. et al. IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J. Clin. Oncol. 28, 2348–2355 (2010). PMID: 20368543  

63. Marcucci G, et al., (2010). IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 28:2348–2355, PMID 20368543.

64. Feng, J.-H. et al. Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. Am. J. Blood Res. 2, 254 (2012). PMID: 23226625  

64. Feng J-H, et al., (2012). Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. Am J Blood Res 2:254, PMID 23226625.

65. Cuyàs, E. et al. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget 6, (2015). PMID: 25980580  

65. Cuyàs E, et al., (2015). Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget 6(14):12279-12296, PMID 25980580.

66. Molenaar, R. J. et al. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1 -mutated or IDH2 -mutated solid tumours. BMJ Open 7, e014961 (2017). PMID: 28601826  

66. Molenaar RJ, et al., (2017). Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1 -mutated or IDH2 -mutated solid tumours. BMJ Open 7:e014961, PMID 28601826.

67. Seltzer, M. J. et al. Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1. Cancer Res. 70, 8981–8987 (2010). PMID: 21045145  

67. Seltzer MJ, et al., (2010). Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70:8981–8987, PMID 21045145.

68. Elhammali, A. et al. A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor. Cancer Discov. 4, 828–839 (2014). PMID: 24740997  

68. Elhammali A, et al., (2014). A high-throughput fluorimetric assay for 2-Hydroxyglutarate identifies zaprinast as a glutaminase inhibitor. Cancer Discov 4:828–839, PMID 24740997.

69. Emadi, A. et al. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp. Hematol. 42, 247–251 (2014). PMID: 24333121  

69. Emadi A, et al., (2014). Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol 42:247–251, PMID 24333121.

70. Mohrenz, I. V. et al. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 18, 1416–1425 (2013). PMID: 23801081  

70. Mohrenz IV, et al., (2013). Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 18:1416–1425, PMID: 23801081.

71. Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380–384 (2012). PMID: 22101433  

71. Metallo CM, et al., (2012). Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481:380–384, PMID 22101433.

72. Calvert, A. E. et al. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell Rep. 19, 1858–1873 (2017). PMID: 28564604  

72. Calvert AE, et al., (2017). Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation. Cell Rep 19:1858–1873, PMID 28564604.

73. Konopleva, M. et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 6, 1106–1117 (2016). PMID: 27520294  

73. Konopleva M, et al., (2016). Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 6:1106–1117, PMID 27520294.

74. Saha, S. K. et al. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov. 6, 727–739 (2016). PMID: 27231123  

74. Saha SK, et al., (2016). Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov 6:727–739, PMID 27231123.

75. Boutzen, H. et al. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J. Exp. Med. 213, 483–497 (2016). PMID: 26951332  

75. Boutzen H, et al., (2016). Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J Exp Med 213:483–497, PMID 26951332.

76. Zarei, M. et al. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Cancer Res. 77, 4460–4471 (2017). PMID: 28652247  

76. Zarei M, et al., (2017). Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells. Cancer Res 77:4460–4471, PMID 28652247.

77. Kim, S. Y., Yoo, Y. H. & Park, J.-W. Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity. Biochem. Biophys. Res. Commun. 433, 260–265 (2013). PMID: 23500467  

77. Kim SY, et al., (2013). Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity. Biochem Biophys Res Commun 433:260–265, PMID 23500467.

78. Wang, J.-B., Dong, D.-F., Wang, M.-D. & Gao, K. IDH1 Overexpression Induced Chemotherapy Resistance and IDH1 Mutation Enhanced Chemotherapy Sensitivity in Glioma Cells in Vitro and in Vivo. Asian Pac. J. Cancer Prev. 15, 427–432 (2014). PMID: 24528069

78. Wang J-B, et al., (2014). IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in glioma cells in vitro and in vivo. Asian Pac J Cancer Prev 15:427–432, PMID 24528069.

79. Wang, P. et al. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep. 13, 2353–2361 (2015). PMID: 26686626  

79. Wang P, et al., (2015). Oncometabolite D-2-Hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents. Cell Rep 13:2353–2361, PMID 26686626.

80. Buckner, J. C. et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N. Engl. J. Med. 374, 1344–1355 (2016). PMID: 27050206  

80. Buckner JC, et al., (2016). Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374:1344–1355, PMID 27050206.

81. SongTao, Q. et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 103, 269–273 (2012). PMID: 22034964  

81. SongTao Q, et al., (2012). IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103:269–273, PMID 22034964.

82. Molenaar, R. J. et al. IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clin. Cancer Res. 24, 1705–1715 (2018). PMID: 29339439  

82. Molenaar, R. J. et al. IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clin. Cancer Res. 24, 1705–1715 (2018). PMID: 29339439